Clinic notes show BPC-157 use rising fastest among younger men

The study was a randomized controlled experiment in 32 male Sprague-Dawley rats ¹. Researchers assigned the animals to four groups: a control group, BPC-157 at 10 micrograms per kilogram of body weight per day, TB-500 at 60 micrograms per kilogram per day, or both peptides together ¹. The treatments were injected into the belly cavity for four weeks ¹. After that, the team measured the force needed to break the repaired tendon, scored the tissue with two rating systems called Bonar and Movin, and stained it for collagen type I and type III, the main structural proteins in tendon ¹.

Maximum load was higher in the BPC-157 and TB-500 groups than in the control group, but the difference reached statistical significance, meaning it was unlikely to be due to chance, only for TB-500 ¹. In the tissue scoring, total Bonar scores were significantly lower, which means less damage, in the TB-500 group, and total Movin scores were significantly lower in the TB-500 and combination groups ¹. The BPC-157 alone group had numerically lower scores, but the difference was not statistically significant ¹. The limitation is that this was a single surgical cut model measured at one point four weeks after injury, with eight rats per group, and it did not test different doses or longer-term remodeling ¹.

A separate research team reviewed de-identified clinical notes, meaning names and identifying details were removed, from a U.S. network of health systems ². They used computer programs that read and sort text, called large language models, and had physicians check the output ². Of 1,536 patients whose notes mentioned BPC-157, 1,039 had documented use ². The number of newly confirmed users every three months increased 33-fold between 2020 and 2026 ².

Among patients with newly documented use, the share who were men rose from 57% in 2020 to 70% in 2026, while the average age fell from 55 years to 49 years ². Users were 95.9% White compared with 78% of the background care population, a 1.23-fold enrichment ². For the 205 patients with a documented consumer source, compounding pharmacies, which prepare custom medicines, accounted for 36%, and sellers outside regulated pharmacy channels, often called gray-market peptide vendors, accounted for 35% ². Of 1,039 users, 525 had a documented other substance used at the same time; the most common were testosterone at 17.0%, nonsteroidal anti-inflammatory drugs (NSAIDs) at 14.7%, TB-500 at 12.9%, and corticosteroids at 11.7% ². Documented non-drug supports included physical therapy at 15.3%, surgery at 12.6%, exercise counseling at 8.3%, and diet counseling at 6.3% ². Reasons for use were documented for 644 patients, and pain accounted for 33% of all 1,039 users ².

The extraction was 96.0% accurate for co-therapies and 74.4% accurate for non-drug supports ². The limitation is that the records only capture what clinicians wrote, not verified use or outcomes, and consumer source and non-drug supports were available for only a subset ².

A 2026 review by Pietrzyk and colleagues searched three research databases and followed a standard checklist called PRISMA to assess BPC-157 activity across the gut-brain axis, the two-way communication between the digestive tract and the brain ³. The review reports that experimental data show BPC-157 can protect cells, reduce inflammation, and support regrowth in early-stage models ³. In those models, BPC-157 increased nerve cell survival, promoted the growth of new blood vessels, and strengthened nerve connections, a process called synaptic plasticity ³. It also changed activity in brain chemical systems that use dopamine, serotonin, and GABA ³. Animal studies described better motor coordination, cognitive function, and repair after nervous system damage ³.

The review authors note that early clinical studies suggest a favorable safety profile, but evidence that BPC-157 actually works in people remains limited ³. The human evidence is thin: a two-person intravenous safety pilot, where researchers gave BPC-157 into a vein, reported no adverse effects ⁴. Small uncontrolled studies, meaning they lacked a comparison group, reported symptom relief for interstitial cystitis, a painful bladder condition, and knee pain ⁵. None of those human studies established efficacy ⁶.

Earlier preclinical work has linked BPC-157 to blood vessel growth, protection of the thin cell layer lining blood vessels, called endothelial cells, and relaxation of blood vessels driven by nitric oxide ⁸. In human internal mammary artery studied in the laboratory, the relaxation depended on intact endothelial cells and nitric oxide signaling ⁸. Animal studies have reported reduced oxidative stress, meaning less chemical damage to cells, and reduced cell death while increasing VEGF, a signal that encourages blood vessel growth ⁹. Other animal work reported better ligament healing ¹¹ and protection in ischemia-reperfusion injury, the damage that occurs when blood flow returns after a period without oxygen, across muscle, liver, and brain ¹⁰.

A systematic review of orthopaedic sports medicine concluded that human evidence is limited and uncontrolled ⁶. The new clinical note data do not change that conclusion; they show rising real-world use and patient-reported reasons, but they are observational and cannot establish effect ². The 2026 rat tendon study adds a point that does not line up with BPC-157 alone. In that model, TB-500 and the combination produced statistically significant improvements in tendon structure, while BPC-157 alone did not reach significance for total scores ¹. Earlier animal data, including Cerovecki 2010 on ligament healing, leaned toward improved repair ¹¹. Most animal data still point toward enhanced soft-tissue healing, but the 2026 study suggests that the size and consistency of the effect may depend on the specific injury, outcome, and comparator ¹.

Study or data type	What it found
2026 rat Achilles study	TB-500 and the combination improved tendon structure scores; BPC-157 alone did not reach significance 1
2026 clinical note review	Documented BPC-157 use rose 33-fold, with new users younger and more often male 2
Earlier animal studies	Point toward better ligament and soft-tissue healing 11
Human studies to date	Small and uncontrolled; no efficacy established 6
Regulatory status	Not FDA approved; WADA prohibited 14

Regulatory status remains unchanged: BPC-157 is not approved by the U.S. Food and Drug Administration (FDA) and is prohibited by WADA, the World Anti-Doping Agency ¹⁴.

The gap between rising use and controlled human data is wide. No randomized clinical trial has established an effective dose, schedule, or indication for BPC-157 in humans ⁶. The human studies to date are small and uncontrolled, meaning they lack a comparison group. A pilot that gave up to 20 mg into a vein to two people reported no adverse effects ⁴. A bladder pain pilot used a single 10 mg injection directly into the bladder and reported symptom relief in a small sample ⁵. A knee pain study reported relief after injection into the joint, but it was also uncontrolled ⁶.

These studies did not randomize participants or blind outcome assessors, so the effects could reflect placebo, an inactive treatment, or natural recovery ⁶. The clinical note review is a preprint, meaning it has not yet passed formal peer review, based on clinician documentation, which can vary in completeness and accuracy, and the non-drug support extraction had only 74.4% accuracy ². The rat tendon study used one injury model, one four-week window, and belly-cavity delivery, so it cannot answer whether different routes or durations would change the result ¹. The gut-brain axis review describes early changes in brain chemical systems, but there are no human efficacy trials for neuropsychiatric or neurodegenerative conditions ³. Long-term safety, particularly around blood vessel growth in people with cancer or unstable blood vessels, remains unknown ⁹. Until controlled human data are available, the evidence can describe use patterns and mechanisms, but it cannot confirm benefit.